Nemorubicin

This classification denotes an anthracycline antibiotic with the molecular formula C32H37NO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7618O47BQM, chemically known as 5,12-naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-((2,3,6-trideoxy-3-(2-methoxy-4-morpholinyl)-alpha-l-lyxo-hexopyranosyl)oxy)-, (8s-cis)- but generally known as nemorubicin, which bears US NIH Compound Identifier 65907. European Medicines Agency schedules Nemorubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09192MIG. The term NEMORUBICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). NEMORUBICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nemorubicin under HS 29419000 and SITC 54139. As of Q4 2014, NEMORUBICIN remains the US FDA Preferred Term for this commodity. Nemorubicin bears US NLM identifiers UMLS ID C2827283 and NCI Concept Code C83999. SMILES: O(C1OC(C(O)C(N2CC(OCC2)OC)C1)C)C1CC(O)(CC2C1C(O)C1C(C2O)C(=O)C2C(C1=O)C(OC)CCC2)C(=O)CO.